Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Long-Term Debt Repayments (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $462000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Long-Term Debt Repayments fell 98.74% to $462000.0 in Q1 2025 year-over-year; TTM through Dec 2025 was $462000.0, a 98.75% decrease, with the full-year FY2025 number at $462000.0, down 98.75% from a year prior.
  • Long-Term Debt Repayments was $462000.0 for Q1 2025 at Akebia Therapeutics, up from -$1000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $36.7 million in Q1 2024 to a low of -$1000.0 in Q4 2024.
  • A 4-year average of $12.8 million and a median of $8.0 million in 2023 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 129.54% in 2024; the steepest drop was 100.01% in 2024.
  • Akebia Therapeutics' Long-Term Debt Repayments stood at $33.0 million in 2022, then plummeted by 75.76% to $8.0 million in 2023, then crashed by 100.01% to -$1000.0 in 2024, then skyrocketed by 46300.0% to $462000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Long-Term Debt Repayments are $462000.0 (Q1 2025), -$1000.0 (Q4 2024), and $374000.0 (Q2 2024).